Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Rating) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.67 and traded as low as $1.42. Bolt Biotherapeutics shares last traded at $1.53, with a volume of 236,076 shares trading hands.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. Morgan Stanley cut their price objective on shares of Bolt Biotherapeutics from $5.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday. HC Wainwright initiated coverage on shares of Bolt Biotherapeutics in a research note on Tuesday, October 4th. They set a “buy” rating and a $8.00 target price for the company.
Bolt Biotherapeutics Trading Down 4.5 %
The stock’s 50 day moving average is $1.38 and its two-hundred day moving average is $1.67. The company has a market capitalization of $55.36 million, a PE ratio of -0.59 and a beta of 0.99. The company has a quick ratio of 7.23, a current ratio of 7.23 and a debt-to-equity ratio of 0.11.
Hedge Funds Weigh In On Bolt Biotherapeutics
A number of large investors have recently added to or reduced their stakes in the company. Occudo Quantitative Strategies LP raised its holdings in Bolt Biotherapeutics by 19.5% in the second quarter. Occudo Quantitative Strategies LP now owns 30,816 shares of the company’s stock worth $63,000 after purchasing an additional 5,028 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Bolt Biotherapeutics by 13.0% during the first quarter. Bank of New York Mellon Corp now owns 91,293 shares of the company’s stock valued at $249,000 after acquiring an additional 10,475 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Bolt Biotherapeutics by 130.4% during the third quarter. Tower Research Capital LLC TRC now owns 18,537 shares of the company’s stock valued at $28,000 after acquiring an additional 10,492 shares in the last quarter. PDT Partners LLC acquired a new position in shares of Bolt Biotherapeutics during the first quarter valued at about $33,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Bolt Biotherapeutics during the second quarter valued at about $30,000. 71.13% of the stock is currently owned by institutional investors.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.
- Get a free copy of the StockNews.com research report on Bolt Biotherapeutics (BOLT)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.